Skip to content
Back to explorer
Printable monograph

Oral selective estrogen-receptor degrader (SERD)

Camizestrant

Etcamah · CAMI

Oral selective estrogen-receptor degrader (SERD) · approved 2026 · 10 citations

Up to date· through 2026
Fairly sourced5/9 · 5 signals
  • Met: 10 citations
  • Not met: 12+ references
  • Not met: Accrued over 10+ years (span: 3y)
  • Met: Beyond single case reports
  • Met: High-impact journal
  • Met: Landmark reference
  • Met: Current through 2026
  • Not met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

An oral SERD switched in for the aromatase inhibitor when an ESR1 mutation appears in circulating tumor DNA. The kidney story belongs to its CDK4/6 partner: camizestrant does not block creatinine secretion, and its own arm had fewer creatinine rises than the comparator.

MildOral selective estrogen-receptor degrader (SERD)
HR-positive, HER2-negative locally advanced or metastatic breast cancer in adults, with a CDK4/6 inhibitor (abemaciclib, palbociclib or ribociclib), upon detection of an ESR1 mutation during aromatase inhibitor plus CDK4/6 inhibitor therapy, by an FDA-authorized test (SERENA-6; accelerated approval)Studied as monotherapy against fulvestrant after prior endocrine therapy (SERENA-2, phase 2)

Kidney summary

Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.

Renal dosing
Not in the atlas's table of label-specified renal dose changes; the Dosing section has the full entry.
Hemodialysis
Not removed by hemodialysis
Not studied in kidney failure; with an apparent volume of distribution of 1,888 L, a ~23-hour half-life and 4.8% of a dose excreted unchanged in urine (FDA label), intermittent hemodialysis would reach very little of the body burden. No post-dialysis dose is defined, and the label calls the effect of CLcr <30 and ESKD on exposure unknown.
The atlas summary. Full prose in the Dialyzability section.
FDA boxed warning
Yes
Label: ETCAMAH, Sep 2026. Not necessarily about the kidney. FDA label section.
§01

Signature kidney injury

No renal lesion is attributed to camizestrant, and SERENA-6's comparator arm is what lets that be said rather than assumed. Every patient in the trial took a CDK4/6 inhibitor, and in the FDA label's laboratory table creatinine increased from baseline in 16% of patients on camizestrant with a CDK4/6 inhibitor (grade 3-4 0.6%; N=155) against 20% on an aromatase inhibitor with a CDK4/6 inhibitor (grade 3-4 1.3%; N=155) - lower on the camizestrant arm. The label also reports that camizestrant does not inhibit the tubular creatinine transporters OCT2, MATE1 or MATE2-K in vitro, so the creatinine rise clinicians see on this regimen is best read as the CDK4/6 inhibitor's. The label has no renal warning; its boxed warning is arrhythmia risk with QTc-prolonging drugs. SERENA-6 is published (Bidard, N Engl J Med 2025), but the renal laboratory rows come from the label.Source: No drug-attributable renal incidence: creatinine increased 16% all-grade / 0.6% grade 3-4 on camizestrant + CDK4/6 inhibitor (N=155) versus 20% / 1.3% on aromatase inhibitor + CDK4/6 inhibitor (N=155), FDA label SERENA-6 laboratory table

§02

Renal toxicities, ranked

This agent's defining kidney lesion — its #1 signature. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

  1. Prerenal / Hemodynamic AKI#1 · Signaturequalitative — no citable incidence

    Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.

§03

Kidney injury

Mechanism of kidney injury

No direct nephrotoxic mechanism is established, and the label's in vitro transporter data argue against the one the regimen is known for. Camizestrant is cleared mainly by CYP3A and UGT1A4 metabolism: after a radiolabelled 75 mg dose, 65% of radioactivity was recovered in feces (14.5% unchanged) and 17% in urine (4.8% unchanged). In vitro it inhibits P-gp, BCRP and OATP1B1 but does not inhibit OCT2, OAT1, OAT3, MATE1 or MATE2-K - the proximal-tubule transporters whose blockade by abemaciclib raises serum creatinine without lowering true GFR. Its cardiac effects are pharmacological: a nonclinical study attributes the dose-dependent fall in heart rate to reduced sinoatrial-node pacemaker (HCN4 'funny') current, and the label's boxed warning concerns QTc prolongation with ribociclib or other QTc-prolonging drugs. The kidney enters that story through the electrolytes, not through a lesion: the label directs that electrolyte abnormalities be assessed and corrected before the first dose and during treatment.

Clinical presentation

There is no characteristic renal presentation. The likeliest renal finding is a modest, stable creatinine rise that arrived with the CDK4/6 inhibitor - most often abemaciclib - and persists after the switch, with a normal urinalysis and no change in cystatin C. Diarrhea is the partner's other renal route: in the SERENA-1 combination cohorts it was the commonest adverse event with abemaciclib (87.5% at camizestrant 75 mg), and volume or potassium loss from it matters twice on this drug, once for prerenal physiology and once for the QTc. Corrected calcium decreased from baseline in 17% of camizestrant-arm patients against 12% on the comparator, none of them grade 3 or 4, in a regimen whose ECG requirements make the calcium worth knowing.

Management

No camizestrant-specific renal management exists, because no renal lesion is attributed to it. A creatinine rise on the regimen calls first for the question of when it began: a rise dating to the start of abemaciclib or another CDK4/6 inhibitor, stable, with a bland urinalysis and an unchanged cystatin C-based eGFR, is the partner's secretion effect and needs no dose change. Before reducing the dose of a renally cleared co-medication on the strength of that rise, confirm it with a cystatin C-based estimate. A rise that is new, progressive or accompanied by proteinuria, hematuria or an active sediment needs its own workup - volume status after diarrhea, obstruction, contrast, an interacting drug - before either drug is blamed. Camizestrant's label recommends no dose reductions for adverse reactions; it is withheld for QTc prolongation, symptomatic bradycardia, grade 2 or higher visual disturbance or other grade 3 or higher reactions, and the CDK4/6 inhibitor is managed by its own label.Lesion-level management framework

Risk factors

  • Abemaciclib as the CDK4/6 partner: it blocks tubular creatinine secretion and causes frequent diarrhea, the regimen's two routes to a creatinine rise
  • Hypokalemia, hypomagnesemia or hypocalcemia, which add to the QTc risk the boxed warning describes, especially with diarrhea on abemaciclib
  • Ribociclib as the CDK4/6 partner: it prolongs the QTc itself and, as a strong CYP3A inhibitor, roughly doubles camizestrant exposure
  • Creatinine clearance below 30 mL/min or end-stage kidney disease - the label states the effect on camizestrant pharmacokinetics there is unknown
  • Baseline bradycardia or heart-rate-lowering co-medication such as beta-blockers, since the label asks for more frequent heart-rate checks in the first 30 days

Prevention

  • Assess and correct electrolyte abnormalities before the first dose, as the boxed warning directs, so a low potassium, magnesium or calcium does not compound the QTc risk
  • Obtain an ECG before starting and avoid adding other QTc-prolonging or heart-rate-lowering drugs where alternatives exist
  • Replace fluid and electrolytes promptly when CDK4/6-inhibitor diarrhea starts, which protects both against prerenal azotemia and against a potassium drop that raises arrhythmia risk
Anticancer mechanism· how it treats cancer

Oral selective estrogen-receptor degrader (SERD) and complete estrogen-receptor antagonist that binds estrogen receptor alpha, including the ESR1-mutant receptor that confers resistance to aromatase inhibitors, and drives its degradation. Given as 75 mg orally once daily with a CDK4/6 inhibitor (abemaciclib, palbociclib or ribociclib) that is continued at the dose the patient was already taking. The September 2026 approval is an accelerated approval based on progression-free survival measured from detection of the ESR1 mutation, and selection requires an FDA-authorized plasma test repeated every 3 months during first-line therapy.

§04

Clinical depth

Renal dose adjustment

No renal dose adjustment is recommended or defined. The label has no renal-impairment subsection; its pharmacokinetics section reports no clinically significant differences at creatinine clearance 30 to below 90 mL/min (modified Cockcroft-Gault), and states that the effect of clearance 15 to below 30 mL/min and of end-stage kidney disease is unknown. The dose is 75 mg once daily and the label recommends no dose reductions for adverse reactions. The dose changes it does make are for severe hepatic impairment and for CYP3A inducers, and both depend on which CDK4/6 inhibitor is the partner - 75 mg every other day in severe (Child-Pugh C) hepatic impairment when the partner is the one CDK4/6 inhibitor that strongly inhibits CYP3A, and 150 mg once daily alongside an unavoidable moderate CYP3A inducer when the partner is either of the other two.

Dialyzability & ESKD dosing

Not studied, and unlikely to be meaningfully removed. The label gives an apparent volume of distribution of 1,888 L and a terminal half-life of about 23 hours, and only 4.8% of a dose appears unchanged in urine, so intermittent hemodialysis would reach a very small fraction of the body burden. No post-dialysis timing or supplemental dose is defined, and because end-stage kidney disease was not characterized, use in dialysis patients rests on that inference rather than on measured data. Peritoneal dialysis and CRRT are not characterized.

Differential diagnosis

The partner drug comes first. A creatinine rise on camizestrant plus abemaciclib is, until shown otherwise, abemaciclib's blockade of tubular creatinine secretion - the CDK4/6-inhibitor literature finds most such rises are pseudo-AKI on cystatin C. After that, work the usual differential for a patient with metastatic breast cancer: prerenal physiology from diarrhea or poor intake, obstruction from nodal or retroperitoneal disease, hypercalcemia from bone metastases, contrast, and nephrotoxic co-medications. Camizestrant itself is not a tubular, interstitial or glomerular toxin on present evidence, and the trial's comparator arm - more creatinine rises without it - argues against attributing one to it.

Monitoring

  • ECG before the first dose, weekly for the first 2 weeks and periodically thereafter, per the label
  • Serum electrolytes at baseline and during treatment as clinically indicated, per the label - in practice potassium, magnesium and calcium, the QTc-relevant ones - with closer checks during CDK4/6-inhibitor diarrhea
  • Heart rate more often in the first 30 days if baseline rate is under 60 beats per minute or the patient takes a heart-rate-lowering drug
  • Serum creatinine with a cystatin C-based estimate when creatinine rises, to separate the partner drug's secretion effect from true GFR loss
  • Visual symptoms at each visit, since grade 2 or higher visual disturbance is a reason to withhold the drug

Key trials & series

  • SERENA-6 (NCT04964934; phase 3, double-blind, placebo-controlled) - 3,256 patients on first-line aromatase inhibitor plus CDK4/6 inhibitor were tested for ESR1 mutations in circulating tumor DNA, and 315 with an emerging mutation and no radiological progression were randomized to switch to camizestrant 75 mg with continued CDK4/6 inhibitor or to stay on the aromatase inhibitor. Median progression-free survival was 16.0 versus 9.2 months at the interim analysis (Bidard, N Engl J Med 2025) and 16.8 versus 9.2 months at extended follow-up (Turner, Lancet Oncol 2026). Neither paper's abstract reports a renal laboratory row; the label's creatinine comparison comes from this trial's 155-patient safety arms.
  • SERENA-1 combination cohorts (Baird, Clin Cancer Res 2025) - phase 1 camizestrant with abemaciclib, palbociclib or ribociclib in pretreated disease; diarrhea dominated with abemaciclib (87.5% at 75 mg) and neutropenia with palbociclib and ribociclib. No renal endpoint.
  • SERENA-1 monotherapy (Hamilton, Ann Oncol 2024) - dose escalation from 25 to 450 mg in 108 patients; visual effects (56%) and sinus bradycardia (44%) were the commonest treatment-related events, with no grade 3 or higher treatment-related events at 150 mg or below. No renal endpoint.
  • SERENA-2 (Oliveira, Lancet Oncol 2024) - randomized phase 2 of camizestrant 75 or 150 mg versus fulvestrant after prior endocrine therapy (240 patients); median progression-free survival 7.2 and 7.7 versus 3.7 months. No renal endpoint.

Clinical pearls

  • Two arms, same CDK4/6 inhibitor, more creatinine rises on the arm without camizestrant: 20% against 16%. That comparison is the reason no lesion is attributed to the drug.
  • Camizestrant does not inhibit OCT2, MATE1 or MATE2-K. If creatinine rose with abemaciclib and stays up after the switch, it is still abemaciclib's.
  • The kidney's job on this drug is electrolytes. The boxed warning asks for them to be corrected before the first dose and kept normal, and abemaciclib diarrhea is the commonest way they fall.
  • Ribociclib doubles camizestrant exposure and prolongs the QTc on its own - the combination behind the boxed warning and the one Torsades de Pointes case in dose-finding.
  • There is no renal dose adjustment, but there is also no data below creatinine clearance 30 or in end-stage kidney disease. 'Not studied' is not 'safe'.
Where it strikes· nephron segments & injury signatures

Nephron segments

Vasculature / Endothelium

Glomerular & peritubular capillaries

§05

References

10 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.

Evidence accrual

10 references · 2023–2026 · 9 since 2024
402023: 1 citation2024: 2 citations2025: 4 citations2026: 3 citations20232026

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

  1. 1.LandmarkFirst-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer.Bidard FC et al. · N Engl J Med · 2025 · PMID 40454637The registrational SERENA-6 interim analysis: of 3,256 patients tested during first-line aromatase inhibitor plus CDK4/6 inhibitor therapy, 315 with an emerging ESR1 mutation were randomized to switch to camizestrant or continue; median progression-free survival 16.0 versus 9.2 months, with discontinuation for adverse events 1.3% versus 1.9%. The abstract reports no renal endpoint; the label's creatinine comparison comes from this trial's safety arms.
  2. 2.Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.Turner NC et al. · Lancet Oncol · 2026 · PMID 42442380SERENA-6 at a median 23.5 months: progression-free survival 16.8 versus 9.2 months and second progression-free survival 25.7 versus 19.1 months; serious adverse events 15% versus 19%, and one sudden death judged possibly related to camizestrant - the cardiac signal behind the label's ECG and electrolyte requirements.
  3. 3.Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2- Advanced Breast Cancer: Results from SERENA-1.Baird RD et al. · Clin Cancer Res · 2025 · PMID 40788187Phase 1 safety of camizestrant with abemaciclib, palbociclib or ribociclib. Diarrhea was the commonest adverse event with abemaciclib (87.5% at camizestrant 75 mg) - the partner-drug route to volume and electrolyte loss this profile names.
  4. 4.LandmarkA phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results.Hamilton E et al. · Ann Oncol · 2024 · PMID 38729567First-in-human monotherapy across 25 to 450 mg in 108 patients: visual effects 56%, sinus bradycardia 44%, fatigue 26% and nausea 15% as treatment-related events, no grade 3 or higher treatment-related events at 150 mg or below, and a half-life of 20 to 23 hours. No renal endpoint.
  5. 5.Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial.Oliveira M et al. · Lancet Oncol · 2024 · PMID 39481395Randomized phase 2 against fulvestrant in 240 patients: median progression-free survival 7.2 months at 75 mg and 7.7 months at 150 mg versus 3.7 months, and no single grade 3 or worse treatment-emergent adverse event in more than two patients (3%) in any group. Monotherapy context; no renal endpoint.
  6. 6.Camizestrant-induced heart rate reduction is mediated via a sinoatrial node pacemaker channel mechanism.Hall A et al. · Toxicol Appl Pharmacol · 2026 · PMID 41903809Nonclinical mechanism for the heart-rate fall: reduced hHCN4 and sinoatrial-node 'funny' current, persisting after combined autonomic blockade. Explains why bradycardia, and the QTc risk it amplifies, is the drug's organ toxicity rather than a renal one.
  7. 7.LandmarkRenal adverse events associated with cyclin-dependent kinase 4/6 inhibitors.Izzedine H et al. · Cancer Treat Rev · 2025 · PMID 41385991Onconephrology review of the CDK4/6 inhibitors every SERENA-6 patient took: abemaciclib carries the largest creatinine signal, through OCT2/MATE secretion blockade rather than true GFR loss, with cystatin C as the discriminator. The source for reading a creatinine rise on this regimen as the partner's.
  8. 8.Pseudo acute kidney injury in patients receiving CDK4/6 inhibitors.Buijs SM et al. · Br J Cancer · 2025 · PMID 39930149Cohort evidence that most creatinine rises on CDK4/6 inhibitors are pseudo-AKI when checked against a cystatin C-based eGFR - the basis for measuring cystatin C before acting on a creatinine rise on this regimen.
  9. 9.The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance.Lawson M et al. · Cancer Res · 2023 · PMID 37725704Preclinical pharmacology behind the mechanism description: selective ER degradation and complete ER antagonism in ESR1 wild-type and ESR1-mutant cell lines and patient-derived xenografts, including fulvestrant-resistant models, with activity alongside palbociclib or abemaciclib.
  10. 10.Camizestrant: First Approval.Lee A · Drugs · 2026 · PMID 42786359Development and approval summary: first approved in the United Arab Emirates in May 2025, then in Saudi Arabia, Japan, the EU, Canada, the UK and the USA, for HR-positive, HER2-negative advanced breast cancer with an ESR1 mutation emerging during first-line endocrine therapy, in combination with a CDK4/6 inhibitor.
FDA label — boxed warning & renal dosing· boxed warning

Quoted verbatim from this agent's current FDA label (Sep 2026) — not paraphrased or interpreted. Full label on DailyMed .

Boxed warning

WARNING: ARRHYTHMIA RISK WITH CONCOMITANT USE OF QTc INTERVAL PROLONGING DRUGS ETCAMAH in combination with ribociclib, a QTc interval prolonging drug and a strong CYP3A inhibitor, or in combination with other QTc interval prolonging drugs, can increase the risk of Torsades de Pointes, other ventricular arrhythmias, and sudden death ( 5.1 , 5.2 , 7.1 ). Avoid concomitant use of ETCAMAH with products (other than ribociclib) known to prolong the QTc interval and/or have a known risk of Torsades de Pointes. If concomitant use with other products cannot be avoided, monitor the QTc interval more frequently ( 5.1 , 7.3 ). Obtain ECG prior to initiation and monitor heart rate and QTc interval during treatment. Assess and correct electrolyte abnormalities prior to initiation and during treatment. Withhold ETCAMAH until resolution of QTc interval prolongation and resume or permanently discontinue ETCAMAH based on severity. ( 2.2 , 2.4 ) WARNING: ARRHYTHMIA RISK WITH CONCOMITANT USE OF QTc INTERVAL PROLONGING DRUGS See full prescribing information for complete boxed warning. • ETCAMAH in combination with ribociclib, a QTc interval prolonging drug and a strong CYP3A inhibitor, or in combination with other QTc interval prolonging drugs, can increase the risk of Torsades de Pointes, other ventricular arrhythmias, and sudden death ( 5.1 , 5.2 , 7.1 ). • Avoid concomitant use of ETCAMAH with…

Kidney rows of the label's dosage tables

From the ETCAMAH label (Sep 2026) · DailyMed

No row of this label's dosage table names a kidney term together with a withhold, reduce, resume or discontinue instruction. That covers those four instructions in the tables only: a table can still set a starting dose by creatinine clearance, and the prose can give other kidney instructions. The full label on DailyMed has both.

What gets reported — FAERS

Everything below is FAERS — adverse events someone chose to report, about 14 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.

  • Reporting odds ratio (ROR) — is kidney injury named in this agent's reports more often than in every other drug's? Above 1 means yes, disproportionately.
  • Renal phenotypes — the same question asked separately for each kind of kidney injury, so the ratios differ from the overall one and from each other.
  • Outcomes — a share of this agent's own reports, not of patients: how many were filed as involving a death or a hospitalization. Not a case-fatality rate.
FAERS reported renal phenotypes· 3 reported phenotypes

14 total FAERS reports is below the 50 this atlas requires before quoting an odds ratio, so report counts are shown instead of RORs and none of these counts as a signal. A phenotype missing below was queried and never cleared even the nominal CI bar, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.

What reporting says about this profile's documented lesions

  • Prerenal / Hemodynamic AKINot queried in FAERS — No MedDRA term set is defined for this phenotype, so FAERS was never asked about it.
Crystal / Obstructive Nephropathy
3 reports
Hemorrhagic Cystitis
1 report
Electrolyte Disturbance
2 reports
FAERS outcomes & reporting trend· 1 of 14 reports w/ death · 12 w/ hospitalization

14 reports is below the 50 this atlas requires before quoting a percentage, so the counts are shown instead of shares.

1 of 14

Reported with a death outcome

too few reports to express as a share

12 of 14

Reported with hospitalization

too few reports to express as a share

Reports per year

  • 2015: 0 reports
  • 2016: 0 reports
  • 2017: 0 reports
  • 2018: 0 reports
  • 2019: 0 reports
  • 2020: 0 reports
  • 2021: 0 reports
  • 2022: 0 reports
  • 2023: 4 reports
  • 2024: 2 reports
  • 2025: 3 reports
  • 2026: 5 reports

Reports received per year, 2015–2026 · most recent year is partial.

FAERS adverse-event signal — all organ systems· 7 systems · 14 reports

Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.

Disproportionality (acute kidney injury):ROR 7.2095% CI 0.94–55.03· 1 AKI reports· IC025 −2.59·no disproportionate AKI reporting signal (CI spans 1).
Renal & urinary
Hydronephrosis3Acute Kidney Injury1Cholecystitis Acute1
Hepatobiliary
Alanine Aminotransferase Increased1Aspartate Aminotransferase Increased1Blood Bilirubin Increased1Cholestasis1
Gastrointestinal
Nausea2Abdominal Distension1
General / constitutional
Fatigue2
Cardiac
Arrhythmia1Bradycardia1
Musculoskeletal
Arthralgia1
Vascular
Cerebral Haemorrhage1
Guidelines & consensus· 13

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where Camizestrant sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.
Phenotype-similar agents· the numbered markers on the map above

Vepdegestrant

Veppanu · PROTAC estrogen-receptor degrader

Profile

2026 first PROTAC ER degrader; no meaningful intrinsic renal signal.

PRE
Mild#1 · 100% phenotype match

Elacestrant

Orserdu · Oral selective estrogen-receptor degrader (SERD)

Profile

2023 oral SERD; nausea-dominant, minimal intrinsic nephrotoxicity.

PRE
Mild#2 · 100% phenotype match

Iberdomide

Zenbexus · Cereblon E3 ligase modulator (CELMoD)

Profile

2026 first-in-class CELMoD; no attributable lesion (renal impairment 11% vs 8% on the comparator arm) but exposure rises 1.8x below eGFR 30 off dialysis.

PRE
Mild#3 · 89% phenotype match

Zidesamtinib

Jideytro · ROS1-selective TKI

Profile

2026 TRK-sparing ROS1 TKI; no creatinine abnormality reached the label's >=20% lab-table cutoff — unlike the class's benign pseudo-AKI rise. Renally quiet so far.

PRE
Mild#4 · 89% phenotype match

Casdatifan

HIF-2α inhibitor (investigational)

Profile

Trial-stage RCC HIF-2α inhibitor; renal profile being defined.

PRE
Mild#5 · 89% phenotype match

Dordaviprone

Modeyso · Imipridone (ONC201; DRD2/ClpP)

Profile

2025 imipridone for H3 K27M glioma; renally well tolerated — QT prolongation, not nephrotoxicity, is the safety focus.

PRE
Mild#6 · 89% phenotype match
Compare Camizestrant with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.

Kidney risk across Hormonal / endocrine

Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.

  1. 1Camizestrant· this agentFAERS n/aMild
  2. 1ElacestrantMild
  3. 1LeuprolideMild
  4. 1VepdegestrantFAERS n/aMild
  5. 5DarolutamideMild
  6. 5EnzalutamideMild
  7. 5ImlunestrantMild
  8. 5LanreotideMild
  9. 5OctreotideMild
  10. 10TamoxifenMild
  11. 11BicalutamideFAERS AKIMild
  12. 12MitotaneModerate
  13. 13AbirateroneFAERS AKIModerate

A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.